腹腔热灌注化疗在胃癌腹腔转移治疗中的价值  

Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of gastric cancer

作　　者：吴晓江[1,2] 贾永宁[1,2] 季加孚[1,2] 

机构地区：[1]北京大学肿瘤医院 [2]北京市肿瘤防治研究所胃肠肿瘤外科恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《中国实用外科杂志》2015年第10期1071-1075,共5页Chinese Journal of Practical Surgery

摘　　要：腹腔种植转移是胃癌的主要致死原因,一旦出现,预后极差。近年来,单纯的腹腔种植转移逐渐被认为是一种局部病变,可以采取更为积极的治疗方法,包括腹腔热灌注化疗、腹膜切除等。手术联合腹腔热灌注化疗可以大大降低术后腹腔复发率,腹膜切除联合腹腔热灌注化疗对胃癌合并明显腹腔种植转移也具有较好的治疗效果。选择潜在可获益的病人是获得良好疗效的重要前提。但是目前腹腔热灌注化疗仍然缺少一套标准的流程,还有待于进一步的前瞻性研究结果来使其标准统一。The peritoneal carcinomatosis is the main cause of death for gastric cancer. Once diagnosed, the prognosis is poor extremely. While simple peritoneal carcinomatosis has been considered as localized disease gradually, and more aggressive methods could be adopted including hyperthermic intraperitoneal chemotherapy （HIPEC） and peritoneal resection. Combination of surgery and HIPEC could significantly decrease the recurrence rate, and the combination of CRS and HIPEC could also enhance the therapeutic effect of gastric cancer patients with obvious peritoneal dissemination. Careful selection of the potential beneficiary is the key for better survival. But up to now a standard protocol is demanded highly, and more prospective clinical trials are needed to provide enough evidence for the protocol conformation.

关 键 词：胃癌 腹腔种植转移 腹腔热灌注化疗 肿瘤细胞减灭术 

分 类 号：R6[医药卫生—外科学]